Structure Therapeutics, Inc. Sponsored ADR, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Dolezal from LifeSci Capital maintained a Buy rating on the stock and has a $110.00 price target.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Patrick Dolezal has given his Buy rating due to a combination of factors including the promising results from Structure Therapeutics’ aleniglipron in treating obesity. The Phase 2b ACCESS-1 study demonstrated that aleniglipron, an oral GLP-1, achieved significant weight loss, surpassing the benchmarks set by competitors like Eli Lilly’s orfoglipron. The drug showed placebo-adjusted weight loss of over 11% at a 120mg dose and even higher efficacy in other doses evaluated in the ACCESS-2 study.
Furthermore, the tolerability profile of aleniglipron is favorable, with low discontinuation rates and manageable side effects. The data indicates potential for further improvement in side effects, particularly vomiting, through dose adjustments. This positions aleniglipron as a competitive option with a broad therapeutic index, offering flexibility in dosing and potential for greater weight loss. Consequently, the probability of success for aleniglipron in the obesity market has been increased, reflecting a positive outlook for Structure Therapeutics’ stock.
In another report released on December 2, Stifel Nicolaus also maintained a Buy rating on the stock with a $50.00 price target.